In addition, FTIs have shown some promise in treating a mouse model of progeria, and in May 2007 a phase II clinical trial using the FTI Lonafarnib was started for children with progeria.
Ademais, os FTIs parecen prometedores para o tratamento da proxeria en modelos de ratos, e en 2007 empezou un ensaio clínico en fase II utilizando o FTI Lonafarnib para tratar a proxeria en nenos.